The leading Russian pharmaceutical company Binnopharm Group opened a subsidiary in China and signed cooperation agreements with several Chinese strategic partners

In June 2023, Binnopharm Group established a subsidiary company, Shanghai Binnopharm Chemical Co., Ltd., in the People's Republic of China, becoming the eighth office opened by Binnopharm Group to provide commercial presence of the Russian pharmaceutical holding in different countries.

The Binnopharm Group subsidiary signed agreements with Chinese partners on cooperation in the field of pharmaceutical production, supply of active pharmaceutical ingredients and drug development, worth over 3 billion rubles in the framework of the Russian-Chinese Pharmaceutical Forum taking place in Shanghai on June 20, 2023.

The signing of cooperation agreements with Chinese partners will allow Binnopharm Group to provide its own enterprises located in five regions of Russia, as well as the R&D center, with advanced high-tech equipment and essential pharmaceutical ingredients.

Cooperation with Chinese companies and building partnerships also serve as a platform for further development of the Binnopharm Group export business, access to Chinese market and other markets of South-East Asia. Expanding its international presence is one of the company’s strategic goals, which will create opportunities for business growth and portfolio extension. This will allow Binnopharm Group to get leading positions in the Russian pharmaceutical market and the countries of its presence.

Binnopharm Group's strategic partners include major suppliers of equipment for pharmaceutical companies: Tofflon Science and Technology Group Co., Ltd. and Truking Feiyun Pharmaceutical Equipment (Changsha) Ltd. In 2023-2024, Binnopharm Group plans to upgrade and expand its manufacturing facilities and R&D center. The up-to-day high-tech equipment worth over 1.2 billion rubles will allow to launch production lines for sterile solutions using BFS technology, automatic filling lines for dosing injectable powders in aseptic conditions, capsule production lines, and to establish a plant for production of monoclonal antibodies.

Another important partner of Binnopharm Group in China is the biopharmaceutical company Mabwell Biosciences engaged in the development and production of biological medicines. The strategic partnership will ensure Binnopharm Group to grow expertise in the production of biological products and start production of monoclonal antibodies for treatment of different serious diseases including oncological. Full cycle localization (including drug substance production) and commercial launch in the Russian market of several pharmaceutical products is expected in 2025–2026. The amount of investment needed to execute the project will be more than 1.5 billion rubles.

Also, an agreement was signed with CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. a supplier of active pharmaceutical ingredients, for the production of antimicrobial medicines, the volume of purchases from which in the next year will reach 50 tons and 32 billion units for a total amount of 300 million rubles.

Rustem Muratov, CEO of Binnopharm Group: “The opening of a subsidiary in China today will allow us to develop our production in the short term, upgrade our facilities, develop new products, and provide consumers with high-quality medicines. Our challenge now is to build relationships with Chinese partners. They will become a reliable platform for Binnopharm Group to enter the market of China and other markets of South-East Asia. Today, this is one of the most promising directions of export business development, which will allow the company to lead and demonstrate high growth rates.”